Schedule 13D ownership disclosure
Elicio Therapeutics, Inc.
Security class unavailable · CUSIP: 28657F103
Event date: 2023-08-28
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 8.1600%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-23-225024
- Form type
- SC 13D
- Filer
- Clal Biotechnology Industries Ltd.
- CIK
- CIK 1468950
- Filed
- Aug 30, 2023
- Reporting period
- Aug 28, 2023
- Description
- Schedule 13D beneficial ownership